Core Scientific (CORZ) director Jordan Levy granted 18,575 RSUs

Rhea-AI Filing Summary

Core Scientific, Inc. director Jordan Levy reported receiving an award of 18,575 shares of common stock on February 4, 2026 at a price of $0, reflecting a restricted stock unit grant. Following this grant, he beneficially owns 325,462 shares directly.

The restricted stock units will vest in full on February 3, 2027, provided Levy continues to serve as a non-employee director through that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Jordan

(Last) (First) (Middle)

C/O CORE SCIENTIFIC, INC.

838 WALKER ROAD, SUITE 21-2105

(Street)

DOVER DE 19904

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Core Scientific, Inc./tx [ CORZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		A		18,575(1)	A	$0	325,462	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on February 3, 2027, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date.

	/s/ Todd DuChene, as Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Jordan Levy report for Core Scientific (CORZ)?

Jordan Levy reported an acquisition of 18,575 shares of Core Scientific common stock on February 4, 2026. The shares reflect a restricted stock unit grant and were acquired at a price of $0 per share as part of his director compensation.

How many Core Scientific (CORZ) shares does Jordan Levy own after this Form 4?

After the reported transaction, Jordan Levy beneficially owns 325,462 shares of Core Scientific common stock. These shares are held directly, reflecting his updated stake following the 18,575-share restricted stock unit grant reported on February 4, 2026.

What is the nature of the 18,575-share grant reported by Jordan Levy at Core Scientific (CORZ)?

The 18,575-share grant to Jordan Levy represents a restricted stock unit (RSU) award. These RSUs convert into shares of common stock and are structured as part of his compensation for serving as a non-employee director of Core Scientific.

When do Jordan Levy’s restricted stock units in Core Scientific (CORZ) vest?

Jordan Levy’s restricted stock units will vest in full on February 3, 2027. Vesting is conditioned on his continued service as a non-employee director of Core Scientific through that date, according to the disclosure in the Form 4.

Did Jordan Levy pay for the Core Scientific (CORZ) shares reported in this Form 4?

No cash payment was reported for this grant; the 18,575 shares were acquired at a price of $0 per share. The transaction reflects a restricted stock unit award rather than an open-market purchase of Core Scientific common stock.

Is Jordan Levy a director or officer of Core Scientific (CORZ) in this filing?

In this filing, Jordan Levy is identified as a director of Core Scientific and not as an officer or 10% owner. The RSU grant and resulting share ownership are tied to his role as a non-employee director of the company.